BioPharma Dive2d
Sanofi reaches consumer health deal; Supernus antidepressant fails study
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...
precisionmedicineonline4d
FDA Grants Priority Review to Ultragenyx's BLA for Sanfilippo Syndrome Type A Gene Therapy
The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.
STAT4d
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
Ultragenyx’s BLA for UX111 accepted by FDA for priority review
Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...
Ultragenyx price target raised to $136 from $121 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...
Ultragenyx Pharmaceutical’s (RARE) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...